Planning a pregnancy, with type 1 in the room

What planning means, in the work the household does together

The work of planning a pregnancy with type 1 starts well before the conversation about conception. It begins in the months when the household quietly turns toward the question; the partner who picks up the NICE NG3 page over tea; the conversation with the diabetes team that names planning as the next chapter rather than the next appointment. None of that is medical action; all of it is the shape of planning.

We hold the foundations together at this stage. The reader is the woman with type 1 making the decision; the partner, the household, and the diabetes team are part of the conversation alongside. The first move is rarely a number to hit; it is a conversation to open with the team, and a shared sense that the work the reader has been doing for years is now the foundation the planning rests on.

The three pre-pregnancy targets NICE NG3 anchors

The NICE guideline NG3 for diabetes in pregnancy anchors three pre-pregnancy targets that frame the planning conversation. None of the three is a personal prescription; each is a target that the joint antenatal-diabetes team will read alongside the reader’s own data and the reader’s wider clinical picture. The wording matters: NICE NG3 names “where safely achievable” on the HbA1c target, and the timing of the folic acid and the contraception conversations is designed to be reached without urgency.

The three targets read together rather than separately. Each is a conversation; none is a number the reader hits alone.

The team-based posture: this is not the woman’s work alone

The team that holds the planning conversation typically includes the diabetes consultant, the diabetes specialist nurse, the dietitian, the GP, and (where the trust runs a joint clinic) a midwife who runs the joint antenatal-diabetes clinic. In some trusts the obstetrician joins the planning conversation early; in others the obstetrician joins at the booking visit. The reader’s GP is part of the conversation throughout; the GP is often the route into the higher-dose folic acid prescription and the route into the pre-conception appointment.

We bring the questions to the team together where the household is part of the conversation. The reader is the woman with type 1 making the decision; the partner is part of the planning. The team’s role is to read the data, to weigh the targets against the reader’s personal picture, and to name the next step. The team does not own the timing of the planning; the household does. The team owns the operational pieces (the prescription, the target review, the clinic referral); the reader owns the decision.

Where the AHCL evidence sits at the planning stage

The published evidence base for AHCL in type 1 pregnancy is now strong enough to be part of the planning conversation rather than something only encountered at the booking visit. The AiDAPT trial (Lee 2023) showed that hybrid closed-loop with the CamAPS FX system improved time-in-range in pregnancy compared with standard insulin delivery in the trial cohort. The CRISTAL trial (Benhalima 2024) added further evidence of AHCL benefit during pregnancy in type 1 diabetes with the MiniMed 780G system. Both trials are anchored in pregnancy-specific protocols set by the antenatal-diabetes team; the device is not used in pregnancy with the same target settings as outside pregnancy.

At the planning stage, the question to bring to the team is not which device the reader will use in pregnancy (that conversation lives at the booking visit and is shaped by the trust, the reader’s existing kit, and the antenatal-diabetes team’s experience). The question is whether the reader’s current device and current settings are well placed to carry the work toward the pre-conception HbA1c target, and whether any device or settings conversation should happen now rather than at conception.

The AID Optimiser is a Grade D educational synthesis on a Grade A and B evidence base, reviewed by manufacturer global medical leads at CamAPS, MiniMed, Tandem, and Insulet; it is never endorsed by, validated by, or co-developed with them. It is not a substitute for the conversation with your diabetes team. The Optimiser is not used for pregnancy-specific settings; those live with the antenatal-diabetes team.

Questions to bring to the first pre-pregnancy appointment

The first pre-pregnancy appointment is the conversation that opens the planning chapter. The questions that move the appointment forward most reliably are the specific ones, drawn from the reader’s own data, rather than the broad ones drawn from the literature. We bring them as a household where the partner is part of the conversation; the reader owns the appointment, the partner owns the supporting work that the appointment is built on.

Bring the current HbA1c and the trajectory of the last twelve months. Bring the question of where the personal “safely achievable” target sits in the reader’s picture. Bring the question of whether the 5 mg folic acid prescription has started, and where the prescription will come from (GP or diabetes team). Bring the contraception conversation; what is in place now, and when the team expects the conversation to close. Bring the device conversation if the reader is on AHCL; whether the current device is the device the team would recommend for pregnancy in this trust. Bring the joint antenatal-diabetes clinic referral question; what the route in looks like, and how the planning conversation hands off to the booking visit when the time comes.